Dendrobium officinale Kimura et Migo attenuates diabetic cardiomyopathy through inhibiting oxidative stress, inflammation and fibrosis in streptozotocin-induced mice

Biomedicine and Pharmacotherapy

Volumn 84, Issue , 2016, Pages 1350-1358

  Zhang, Zhihao ^a   Zhang, Duoduo ^a   Dou, Mengmeng ^a   Li, Zhubo ^a   Zhang, Jie ^b   Zhao, Xiaoyan ^a  

^a SOUTHWEST UNIVERSITY   (China)

^b Ninth People's Hospital of Chongqing   (China)

Author keywords

Dendrobium officinale; Diabetic cardiomyopathy; Fibrosis; Inflammation; Lipid accumulation; Oxidative stress

Indexed keywords

ANTIFIBROTIC AGENT; CARDIOVASCULAR AGENT; CHINESE DRUG; CHOLESTEROL; COLLAGEN; COLLAGEN TYPE 1; CREATINE KINASE; DENDROBIUM OFFICINALE EXTRACT; FIBRONECTIN; GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; LACTATE DEHYDROGENASE; MALONALDEHYDE; PLANT EXTRACT; SUPEROXIDE DISMUTASE; TRANSFORMING GROWTH FACTOR BETA; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; CARDIOTONIC AGENT; HERBACEOUS AGENT; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CYTOKINE PRODUCTION; DENDROBIUM OFFICINALE; DIABETIC CARDIOMYOPATHY; DOWN REGULATION; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART SIZE; HEART TISSUE; HERBAL MEDICINE; LIPID STORAGE; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION; WESTERN BLOTTING; ANIMAL; CHEMICALLY INDUCED; DENDROBIUM; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC CARDIOMYOPATHIES; DOSE RESPONSE; DRUG EFFECTS; FIBROSIS; INFLAMMATION; ISOLATION AND PURIFICATION; METABOLISM; PHYSIOLOGY;

ANIMALS; CARDIOTONIC AGENTS; DENDROBIUM; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC CARDIOMYOPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUGS, CHINESE HERBAL; FIBROSIS; INFLAMMATION; MALE; MICE; OXIDATIVE STRESS; STREPTOZOCIN;

EID: 85000925666     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2016.10.074     Document Type: Article

References (36)

1. [1] Zhang, Z., Wang, S., Zhou, S., Yan, X., Wang, Y., Chen, J., Mellen, N., Kong, M., Gu, J., Tan, Y., Zheng, Y., Cai, L., Sulforaphane prevents the development of cardiomyopathy in type 2 diabetic mice probably by reversing oxidative stress-induced inhibition of LKB1/AMPK pathway. J. Mol. Cell. Cardiol. 77 (2014), 42–52.
2. [2] Yan, B., Singla, D.K., Transplanted induced pluripotent stem cells mitigate oxidative stress and improve cardiac function through the Akt cell survival pathway in diabetic cardiomyopathy. Mol. Pharm. 10 (2013), 3425–3432.
3. [3] Rajesh, M., Mukhopadhyay, P., Bátkai, S., Patel, V., Saito, K., Matsumoto, S., Kashiwaya, Y., Horváth, B., Mukhopadhyay, B., Becker, L., Haskó, G., Liaudet, L., Wink, D.A., Veves, A., Mechoulam, R., Pacher, P., Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, inflammatory and cell death signaling pathways in diabetic cardiomyopathy. J. Am. Coll. Cardiol. 56 (2010), 2115–2125.
4. [4] Diao, X., Shen, E., Wang, X., Hu, B., Differentially expressed micrornas and their target genes in the hearts of streptozotocin-induced diabetic mice. Mol. Med. Rep. 4 (2011), 633–640.
5. [5] Giacco, F., Brownlee, M., Oxidative stress and diabetic complications. Circ. Res. 107 (2010), 1058–1070.
6. [6] Regan, T.J., Ahmed, S., Haider, B., Moschos, C., Weisse, A., Diabetic cardiomyopathy: experimental and clinical observations. N. J. Med. 91 (1994), 776–778.
7. [7] Neel, S., Singla, D.K., Induced pluripotent stem (ips) cells inhibit apoptosis and fibrosis in streptozotocin-induced diabetic rats. Mol. Pharm. 8 (2011), 2350–2357.
8. [8] Connelly, K.A., Kelly, D.J., Zhang, Y., Prior, D.L., Martin, J., Cox, A.J., Thai, K., Feneley, M.P., Tsoporis, J., White, K.E., Krum, H., Gilbert, R.E., Functional, structural and molecular aspects of diastolic heart failure in the diabetic (mRen-2)27 rat. Cardiovasc. Res. 76 (2007), 280–291.
9. [9] Palomer, X., Salvado, L., Barroso, E., Vazquez-Carrera, M., An overview of the crosstalk between inflammatory processes and metabolic dysregulation during diabetic cardiomyopathy. Int. J. Cardiol. 168 (2013), 3160–3272.
10. [10] Chen, X.Q., Liu, Z.J., Zhu, G.H., Lang, K.Y., Ji, Z.H., Luo, Y.B., Jin, X.H., Cribb, P.J., Wood, J.J., Gale, S.W., Ormerod, P., Vermeulen, J.J., Wood, H.P., Clayton, D., Bell, A., Orchidaceae. Wu, Z.Y., Raven, P.H., Hong, D.Y., (eds.) Flora of China, vol. 25, 2013, Missouri Botanical Garden Press, St. Louis, 382.
11. [11] Lu, J.J., Suo, N.N., Xu, H., Wang, S., Liu, J.J., Wang, H.Z., Development and characterization of 110 novel EST-SSR markers for dendrobium officinale (Orchidaceae). Am. J. Bot. 99 (2012), e415–e420.
12. [12] Chu, C., Yin, H.M., Xia, L., Cheng, D.P., Yan, J.Z., Zhu, L., Discrimination of Dendrobium officinale and its common adulterants by combination of normal light and fluorescence microscopy. Molecules 19 (2014), 3718–3730.
13. [13] Liu, W.Q., Wang, B.C., Duan, C.R., Li, B., A method for isolating functional RNA from callus of Dendrobium candidum contented rich polysaccharides. Colloids Surf. B: Biointerfaces 42 (2005), 259–262.
14. [14] Lv, G.Y., Yan, M.Q., Chen, S.H., Review of pharmacological activities Dendrobium officinale based on traditional functions. China J. Chin. Mater. Med. 38 (2013), 489–493.
15. [15] Zheng, Q.P., Qiu, D.S., Liu, X.J., Zhang, L., Cai, S.K., Zhang, X.W., Antiproliferative effect of Dendrobium catenatum Lindley polypeptides against human liver, gastric and breast cancer cell lines. Food Funct. 6 (2015), 1489–1495.
16. [16] Xiang, L., Stephen Sze, C.W., Ng, T.B., Tong, Y., Shaw, P.C., Sydney Tang, C.W., Kalin Zhang, Y.B., Polysaccharides of Dendrobium officinale inhibit TNF-a-induced apoptosis in A-253 cell line. Inflamm. Res. 62 (2013), 313–324.
17. [17] Xia, L.J., Liu, X.F., Guo, H.Y., Zhang, H., Zhu, J., Ren, F.Z., Partial characterization and immunomodulatory activity of polysaccharides from the stem of Dendrobium officinale (Tiepishihu) in vitro. J. Funct. Foods 4 (2012), 294–301.
18. [18] Wu, H.S., Xu, J.H., Chen, L.Z., Sun, J.J., Studies on anti-hyperglycemic effect and its mechanism of Dendrobium candidum. China J. Chin. Mater. Med. 29 (2004), 160–163.
19. [19] Pan, L.H., Li, X.F., Wang, M.N., Zha, X.Q., Yang, X.F., Liu, Z.J., Luo, Y.B., Luo, J.P., Comparison of hypoglycemic and antioxidative effects of polysaccharides from four different Dendrobium species. Int. J. Biol. Macromol. 644 (2014), 420–427.
20. [20] Lin, X., Shaw, P.C., Sze, S.C., Tong, Y., Zhang, Y.B., Dendrobium officinale polysaccharides ameliorate the abnormality of aquaporin 5, pro-inflammatory cytokines and inhibit apoptosis in the experimental Sjögren's syndrome mice. Int. Immunopharmacol. 11 (2011), 2025–2032.
21. [21] Xiao, L., Ng, T.B., Feng, Y.B., Yao, T., Wong, J.H., Yao, R.M., Li, L., Mo, F.Z., Xiao, Y., Shaw, P.C., Li, Z.M., Sze, S.C., Zhang, K.Y., Dendrobium candidum extract increases the expression of aquaporin-5 in labial glands from patients with Sjögren's syndrome. Phytomedicine 18 (2011), 194–198.
22. [22] Zhou, G.F., Pang, M.X., Chen, S.H., Lv, G.Y., Yan, M.Q., Comparison on polysaccharide content and PMP-HPLC fingerprints of polysaccharide in stems and leaves of Dendrobium officinale. China J. Chin. Mater. Med. 39 (2014), 795–802.
23. [23] Huynh, K., Bernardo, B.C., McMullen, J.R., Ritchie, R.H., Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways. Pharmacol. Ther. 142 (2014), 375–415.
24. [24] Yilmaz, S., Canpolat, U., Aydogdu, S., Abboud, H.E., Diabetic cardiomyopathy; summary of 41 years. Korean Circ. J. 45 (2015), 266–272.
25. [25] Boudina, S., Abel, E.D., Diabetic cardiomyopathy, causes and effects. Rev. Endocr. Metab. Disord. 11 (2010), 31–39.
26. [26] Falcão-Pires, I., Leite-Moreira, A.F., Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment. Heart Fail. Rev. 17 (2012), 325–344.
27. [27] Bai, Y., Cui, W., Xin, Y., Miao, X., Barati, M.T., Zhang, C., Chen, Q., Tan, Y., Cui, T., Zheng, Y., Cai, L., Prevention by sulforaphane of diabetic cardiomyopathy is associated with up-regulation of Nrf2 expression and transcription activation. J. Mol. Cell. Cardiol. 57 (2013), 82–95.
28. [28] Tschöpe, C., Walther, T., Escher, F., Spillmann, F., Du, J., Altmann, C., et al. Transgenic activation of the kallikrein–kinin system inhibits intramyocardial inflammation, endothelial dysfunction, and oxidative stress in experimental diabetic cardiomyopathy. FASEB J. 19:14 (2005), 2057–2059.
29. [29] Li, Z., Abdullah, C.S., Jin, Z.Q., Inhibition of PKC-θ preserves cardiac function and reduces fibrosis in streptozotocin-induced diabetic cardiomyopathy. Br. J. Pharmacol. 171 (2014), 2913–2924.
30. [30] Lorenzo, O., Picatoste, B., Ares-Carrasco, S., Ramírez, E., Egido, J., Tuñón, J., Potential role of nuclear factor kappa B in diabetic cardiomyopathy. Mediators Inflamm., 2011, 652097, 10.1155/2011/652097.
31. [31] Westermann, D., Van Linthout, S., Dhayat, S., Dhayat, N., Escher, F., Bücker-Gärtner, C., Spillmann, F., Noutsias, M., Riad, A., Schultheiss, H.P., Tschöpe, C., Cardioprotective and anti-inflammatory effects of interleukin converting enzyme inhibition in experimental diabetic cardiomyopathy. Diabetes 56 (2007), 1834–1841.
32. [32] Hou, J., Zheng, D., Fung, G., Deng, H., Chen, L., Liang, J., Jiang, Y., Hu, Y., Mangiferin suppressed advanced glycation end products (AGEs) through NF-κB deactivation and displayed anti-inflammatory effects in streptozotocin and high fat diet-diabetic cardiomyopathy rats. Can. J. Physiol. Pharmacol. 94 (2016), 332–340.
33. [33] Daniels, A., van Bilsen, M., Goldschmeding, R., van der Vusse, G.J., van Nieuwenhoven, F.A., Connective tissue growth factor and cardiac fibrosis. Acta Physiol. 195 (2009), 321–338.
34. [34] Wang, W.K., Wang, B., Lu, Q.H., Zhang, W., Qin, W.D., Liu, X.J., Liu, X.Q., An, F.S., Zhang, Y., Zhang, M.X., Inhibition of high-mobility group box 1 improves myocardial fibrosis and dysfunction in diabetic cardiomyopathy. Int. J. Cardiol. 172 (2014), 202–212.
35. [35] Petrov, V.V., Fagard, R.H., Lijnen, P.J., Stimulation of collagen production by TGF-β1 during differentiation of cardiac fibroblasts to myofibroblasts. Hypertension 39 (2002), 258–263.
36. [36] Lijnen, P., Petrov, V., Fagard, R., Transforming growth factor-β1-mediated collagen gel contraction by cardiac fibroblasts. J. Renin Angiotensin Aldosterone Syst. 4 (2003), 113–118.